Catalyst Pharmaceuticals, Inc. (CPRX)

Catalyst Pharmaceuticals' stock price has been influenced by strong financial results, a share repurchase program, and generic competition for FYCOMPA. Recently, Angelini Pharma S.p.A. announced a definitive agreement to acquire Catalyst Pharmaceuticals for approximately $4.1 billion, or $31.50 per share in cash, expected to close in the third quarter of 2026. Catalyst Pharmaceuticals also announced a settlement of its FIRDAPSE patent litigation with Hetero Labs Ltd., resolving all pending FIRDAPSE patent disputes and pushing any potential generic competition to January 2035.

Demand seasonality is not a prominent factor for Catalyst Pharmaceuticals' products due to the nature of the rare, chronic diseases they treat, where demand is driven by ongoing patient needs and diagnoses rather than seasonal trends.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing, and commercializing medicines for rare neuromuscular and neurological diseases. Its product portfolio includes FIRDAPSE for Lambert-Eaton Myasthenic Syndrome, AGAMREE for Duchenne Muscular Dystrophy, and FYCOMPA for epilepsy. FYCOMPA has faced generic competition since May 2025.

Catalyst Pharmaceuticals has a strong presence in the U.S., which is the cornerstone of its commercial strategy. The company is headquartered in Coral Gables, Florida. FIRDAPSE is available in Canada and Japan through sublicense agreements, and the company is exploring opportunities to expand its global footprint.

Catalyst Pharmaceuticals has received positive recognition for its growth and workplace environment. The company was ranked 11th on Forbes' 2026 List of America's Most Successful Small-Cap Companies, recognized on the 2025 Deloitte Technology Fast 500™ list, and was among BioSpace's 2026 Best Places to Work.

Catalyst Pharmaceuticals has significant institutional ownership, with estimates ranging from 20.98% to 82%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and State Street Corp. Individual ownership accounts for approximately 6.34% of the company, with notable individual insiders including Patrick J. McEnany and Hubert E. Md Huckel.